NVCR News and Press, NovoCure Limited From 04/29/21

Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q1 2021 Earnings Call Apr 29, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q1 2021 Earnings Call Transcript

NovoCure Limited (NVCR) Q1 2021 Earnings Conference Call April 29, 2021, 08:00 AM ET Company Participants Adam Daney - Investor Relations William Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - Chief Financial Officer Uri Weinberg - Chief Science Officer Pr...

Novocure (NVCR) shares are down 4.9% in premarket trading after the company delivered disappointing Q1 results.Novocure missed on both revenues and EPS.The company had a net loss of $4.1M in the quarter compared to net income of $4M in the prior-year period.Revenue of $134.7M, howev...

The following slide deck was published by NovoCure Limited in conjunction with their 2021 Q1 earnings call. For further details see: NovoCure Limited 2021 Q1 - Results - Earnings Call Presentation

NovoCure (NVCR): Q1 GAAP EPS of -$0.04 misses by $0.06.Revenue of $134.7M (+32.3% Y/Y) misses by $3.41M.There were 3,454 active patients at March 31, 2021, representing 12% growth compared to March 31, 2020, and 1% growth compared to December 31, 2020.Press Release For further details see: ...

Quarterly net revenues of $134.7 million with 80% gross margin Interim analysis for phase 3 pivotal LUNAR trial in non-small cell lung cancer concluded with favorable recommendation to continue the trial with reduced sample size Novocure (NASDAQ: NVCR) today reported...

NovoCure (NASDAQ:NVCR) is scheduled to announce Q1 earnings results on Thursday, April 29th, before market open.The consensus EPS Estimate is $0.01 and the consensus Revenue Estimate is $138.11M (+35.6% Y/Y).Over the last 1 year, NVCR has beaten EPS estimates 25% of the time and has beaten re...

Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) application to initiate the KEYNOTE-B36 trial, conducted in collaboration with MSD (Merck & Co., Inc., Kenilworth, NJ, USA). Novocure also...

On April 13, Novocure (NASDAQ: NVCR) stock jumped after the company received a green light to accelerate a pivotal phase 3 study. The investigation involves its medical device, Optune, to treat advanced-stage non-small-cell lung cancer (NSCLC). Optune is a portable device ...

Novocure (NASDAQ: NVCR) hasn't exactly been the kind of stock that fired up investors very much throughout most of 2021. That changed recently, though, with good news providing a huge catalyst for the stock. In this Motley Fool Live video recorded on April 14, 2021 , Motley ...